Phase 1 (85 companies)
Companies with at least one active program at Phase 1.
| Ticker | Company | Therapeutic areas | Phase 1 programs | Lead stage | Programs |
|---|---|---|---|---|---|
| ABSI | Absci Corporation | DermatologyGI/HepatologyWomen's Health | 3 | Phase 1 | 7 |
| ACRS | Aclaris Therapeutics | DermatologyRespiratory | 2 | Phase 2 | 7 |
| ACRV | Acrivon Therapeutics | Oncology | 2 | Phase 2 | 5 |
| ACTU | Actuate Therapeutics | Oncology | 6 | Phase 2 | 7 |
| ABOS | Acumen Pharmaceuticals | Neurology | 1 | Phase 2 | 2 |
| ADAG | Adagene Inc. | Oncology | 3 | Phase 2 | 9 |
| AKBA | Akebia Therapeutics, Inc. | HematologyOphthalmologyRenalRespiratory Rare | 1 | Approved | 14 |
| AKTS | Aktis Oncology, Inc. | Oncology | 8 | Phase 1 | 9 |
| ALDX | Aldeyra Therapeutics, Inc. | DermatologyOncologyOphthalmology Rare | 1 | NDA Submitted | 8 |
| ALLO | Allogene Therapeutics, Inc. | ImmunologyOncology Rare | 4 | Phase 2 | 12 |
| DRTS | Alpha Tau Medical Ltd. | Oncology | 1 | Phase 2 | 5 |
| AMLX | Amylyx Pharmaceuticals, Inc. | MetabolicNeurology Rare | 1 | Phase 3 | 5 |
| ANAB | ANAPTYSBIO, INC | DermatologyGI/HepatologyImmunologyOncology Rare | 3 | Approved | 6 |
| ANNX | Annexon, Inc. | HematologyNeurologyOphthalmologyRenal Rare | 1 | NDA Submitted | 6 |
| APGE | Apogee Therapeutics, Inc. | DermatologyRespiratory | 5 | Phase 2 | 8 |
| RCUS | Arcus Biosciences, Inc. | DermatologyImmunologyOncology | 3 | Phase 3 | 7 |
| ARTV | Artiva Biotherapeutics, Inc. | DermatologyImmunologyOncologyRenal Rare | 5 | Phase 2 | 16 |
| ARVN | ARVINAS, INC. | NeurologyOncology Rare | 9 | Approved | 15 |
| BEAM | Beam Therapeutics Inc. | HematologyMetabolicRespiratory Rare | 4 | Phase 1 | 8 |
| BIOA | BioAge Labs, Inc. | CardiovascularMetabolicOphthalmology | 2 | Phase 1 | 2 |
| BMEA | Biomea Fusion, Inc. | Metabolic | 2 | Phase 2 | 4 |
| BCTX | BriaCell Therapeutics Corp. | Oncology | 1 | Phase 3 | 8 |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | Oncology | 8 | Phase 1 | 8 |
| CCCC | C4 Therapeutics, Inc. | Oncology | 1 | Phase 2 | 2 |
| CABA | Cabaletta Bio, Inc. | DermatologyImmunologyNeurologyRenal Rare | 8 | Phase 1 | 8 |
| CRBU | Caribou Biosciences, Inc. | ImmunologyOncology | 3 | Phase 3 | 4 |
| CLDX | Celldex Therapeutics, Inc. | DermatologyGI/HepatologyImmunologyRespiratory | 1 | Phase 3 | 7 |
| CLRB | Cellectar Biosciences, Inc. | Oncology | 2 | NDA Submitted | 11 |
| IPSC | Century Therapeutics, Inc. | ImmunologyMetabolicRenal Rare | 5 | Phase 1 | 11 |
| CLYM | Climb Bio, Inc. | HematologyImmunologyRenal Rare | 4 | Phase 2 | 7 |
| COGT | Cogent Biosciences, Inc. | HematologyOncology Rare | 4 | NDA Submitted | 7 |
| CBIO | CRESCENT BIOPHARMA, INC. | Oncology | 9 | Phase 1 | 10 |
| CRNX | Crinetics Pharmaceuticals, Inc. | MetabolicOncology Rare | 2 | Approved | 7 |
| CGEM | Cullinan Therapeutics, Inc. | ImmunologyOncology | 6 | NDA Submitted | 7 |
| CTMX | CytomX Therapeutics, Inc. | Oncology | 2 | Phase 1 | 3 |
| DYN | Dyne Therapeutics, Inc. | MetabolicNeurology Rare | 1 | Phase 3 | 10 |
| ENTA | ENANTA PHARMACEUTICALS INC | DermatologyImmunologyInfectious Disease | 2 | Phase 2 | 6 |
| ERAS | Erasca, Inc. | Oncology | 3 | Phase 1 | 4 |
| ETON | Eton Pharmaceuticals, Inc. | GI/HepatologyMetabolicRenal Rare | 1 | Approved | 14 |
| FBRX | Forte Biosciences, Inc. | DermatologyGI/Hepatology | 2 | Phase 2 | 3 |
| GUTS | FRACTYL HEALTH, INC. | Metabolic | 1 | Phase 3 | 3 |
| GANX | Gain Therapeutics, Inc. | MetabolicNeurology Rare | 1 | Phase 1 | 5 |
| GHRS | GH Research PLC | NeurologyWomen's Health | 1 | Phase 2 | 4 |
| GRCE | Grace Therapeutics, Inc. | Neurology Rare | 2 | Phase 3 | 3 |
| IMTX | Immatics N.V. | Oncology | 7 | Phase 2 | 8 |
| IMRX | Immuneering Corp | Oncology | 3 | Phase 3 | 5 |
| IBRX | ImmunityBio, Inc. | Infectious DiseaseOncology | 5 | Approved | 17 |
| INAB | IN8BIO, INC. | ImmunologyOncology | 2 | Phase 2 | 6 |
| JBIO | Jade Biosciences, Inc. | ImmunologyRenal Rare | 1 | Phase 1 | 5 |
| JANX | Janux Therapeutics, Inc. | Oncology | 3 | Phase 1 | 3 |
| KPRX | KIORA PHARMACEUTICALS INC | Ophthalmology Rare | 1 | Phase 2 | 5 |
| KURA | Kura Oncology, Inc. | MetabolicOncology | 7 | Phase 1 | 9 |
| KYMR | Kymera Therapeutics, Inc. | DermatologyRespiratory | 1 | Phase 2 | 5 |
| KYTX | Kyverna Therapeutics, Inc. | ImmunologyNeurologyRenal Rare | 3 | NDA Submitted | 7 |
| LXEO | Lexeo Therapeutics, Inc. | CardiovascularNeurology Rare | 3 | Phase 1 | 10 |
| MRKR | Marker Therapeutics, Inc. | Oncology | 4 | Phase 1 | 4 |
| MDNAF | Medicenna Therapeutics Corp. | Oncology | 2 | Phase 2 | 9 |
| GLUE | Monte Rosa Therapeutics, Inc. | CardiovascularDermatologyMetabolicOncology Rare | 6 | Phase 1 | 8 |
| NRIX | Nurix Therapeutics, Inc. | Oncology | 10 | Phase 2 | 13 |
| OCGN | Ocugen, Inc. | Infectious DiseaseOphthalmology Rare | 5 | Phase 3 | 13 |
| OMER | OMEROS CORP | HematologyNeurologyOncologyRespiratory Rare | 3 | NDA Submitted | 7 |
| ORKA | Oruka Therapeutics, Inc. | DermatologyImmunology Rare | 1 | Phase 2 | 6 |
| OVID | Ovid Therapeutics Inc. | Neurology Rare | 5 | Phase 1 | 6 |
| KTTA | Pasithea Therapeutics Corp. | NeurologyOncology | 1 | Phase 1 | 3 |
| CATX | Perspective Therapeutics, Inc. | Oncology | 3 | Phase 1 | 3 |
| PHIO | Phio Pharmaceuticals Corp. | Oncology | 3 | Phase 1 | 4 |
| RYTM | RHYTHM PHARMACEUTICALS, INC. | Metabolic Rare | 2 | Approved | 13 |
| RCKT | ROCKET PHARMACEUTICALS, INC. | CardiovascularHematologyImmunology Rare | 2 | Approved | 4 |
| SGMT | Sagimet Biosciences Inc. | DermatologyMetabolic | 2 | Phase 3 | 5 |
| SANA | Sana Biotechnology, Inc. | MetabolicOncology | 1 | Phase 1 | 5 |
| SRPT | Sarepta Therapeutics, Inc. | Neurology Rare | 3 | Approved | 10 |
| SLDB | Solid Biosciences Inc. | CardiovascularNeurology Rare | 2 | Phase 3 | 6 |
| GPCR | Structure Therapeutics Inc. | MetabolicRespiratory Rare | 2 | Phase 2 | 5 |
| STRO | SUTRO BIOPHARMA, INC. | Oncology | 1 | Phase 1 | 5 |
| TNGX | Tango Therapeutics, Inc. | Oncology | 5 | Phase 1 | 6 |
| RARE | Ultragenyx Pharmaceutical Inc. | CardiovascularGI/HepatologyMetabolicNeurology Rare | 1 | Approved | 12 |
| QURE | uniQure N.V. | HematologyMetabolicNeurology Rare | 5 | Approved | 6 |
| VNDA | Vanda Pharmaceuticals Inc. | CardiovascularDermatologyGI/HepatologyHematologyImmunologyInfectious DiseaseNeurologyOphthalmology Rare | 5 | Approved | 26 |
| VKTX | Viking Therapeutics, Inc. | GI/HepatologyMetabolicNeurology Rare | 1 | Phase 3 | 9 |
| VIR | Vir Biotechnology, Inc. | Infectious DiseaseOncology Rare | 8 | Phase 3 | 10 |
| VRDN | Viridian Therapeutics, Inc.\DE | Ophthalmology | 3 | NDA Submitted | 6 |
| VYGR | Voyager Therapeutics, Inc. | MetabolicNeurology Rare | 1 | Phase 1 | 7 |
| VTVT | vTv Therapeutics Inc. | MetabolicRespiratory Rare | 1 | Phase 3 | 8 |
| WVE | Wave Life Sciences Ltd. | MetabolicNeurologyRespiratory Rare | 3 | Phase 2 | 5 |
| XENE | Xenon Pharmaceuticals Inc. | Neurology | 3 | Phase 3 | 9 |
No companies match.